Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.84 Increased by +196.55% | 0.85 Decreased by -1.18% |
| May 11, 23 | -0.58 Increased by +28.40% | -0.84 Increased by +30.95% |
| Mar 13, 23 | -0.70 Decreased by -16.67% | -0.91 Increased by +23.08% |
| Mar 9, 23 | -0.75 Decreased by -7.14% | -0.89 Increased by +15.73% |
| Nov 8, 22 | -0.87 Decreased by -42.62% | -0.77 Decreased by -12.99% |
| Aug 8, 22 | -0.81 Decreased by -102.50% | -0.63 Decreased by -28.57% |
| May 9, 22 | -0.60 Decreased by -71.43% | -0.71 Increased by +15.49% |
| Feb 28, 22 | -0.70 Decreased by -45.83% | -0.62 Decreased by -12.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -34.16 M Decreased by -6.58% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -28.55 M Decreased by -17.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -30.71 M Increased by +63.22% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -33.95 M Decreased by -38.20% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -32.05 M Decreased by -96.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -24.32 M Decreased by -71.44% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | -83.50 M Decreased by -344.79% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -24.57 M Decreased by -141.29% | Decreased by N/A% Decreased by N/A% |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.